UCB bags a rival to Soliris in $2.1B buyout deal — but will an increasingly vigilant FTC sign off?
UCB is buying out Ra Pharma $RARX, announcing an acquisition deal that rings up at $48 a share, or $2.1 billion net of cash, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
